Related Experiment Video

Updated: Sep 20, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

[Alternative approaches in the end-stage heart failure]

Serkan Durdu1, Rüçhan Akar, Raif Cavolli

  • 1Department of Cardiovascular Surgery, Ankara University School of Medicine, Ankara, Turkey.

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|September 12, 2003
PubMed

Insights

Limited donor organs restrict cardiac transplantation, a leading treatment for end-stage heart disease. This report explores alternative surgical therapies for patients ineligible for or awaiting heart transplants.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Surgical Innovation

Context:

  • Cardiac transplantation is the primary treatment for end-stage heart disease.
  • Donor organ scarcity limits transplantation to only 1% of eligible candidates.
  • Significant numbers of patients die while awaiting transplantation or face post-transplant complications.

Purpose:

  • To review alternative surgical treatment options for end-stage heart disease.
  • To address the limitations of donor organ availability in cardiac transplantation.
  • To explore strategies for patients who do not meet transplant criteria.

Summary:

  • Cardiac transplantation faces challenges including donor organ shortage, high waiting list mortality (20-40%), and post-transplant complications (20% first-year mortality, 5% annual thereafter).
  • These limitations necessitate research into alternative therapeutic strategies beyond traditional transplantation.
  • The report focuses on summarizing currently available alternative surgical methods for managing end-stage cardiac disease.

Impact:

  • Provides a comprehensive overview of alternative surgical treatments for end-stage heart disease.
  • Offers potential solutions for patients facing donor organ scarcity or transplant ineligibility.
  • Highlights the ongoing need for innovation in cardiac failure management beyond transplantation.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...